Client: Complement Therapeutics

Turning powerful new Complement System insights ninto innovative treatments

Complement Therapeutics is a biotechnology company undertaking innovative research into diseases related to the body’s Complement System, in particular Geographic Atrophy.

Geographic Atrophy is a chronic and progressive eye condition that eventually culminates in blindness. Currently there is no available treatment.

The company is a spinout from The University of Manchester. It was founded by Professor Paul Bishop, Professor Simon J. Clark and Dr Richard Unwin, who have international reputations and world-leading Complement System expertise.

HTP were briefed by the founders to develop a website that would help attract funding to pursue further research and at the same time educate and inform visitors about Complement System diseases – especially Geographic Atrophy – and the potential of the company’s work to benefit the lives of millions.

Client: Complement Therapeutics

Turning powerful new Complement System insights ninto innovative treatments

Complement Therapeutics is a biotechnology company undertaking innovative research into diseases related to the body’s Complement System, in particular Geographic Atrophy.

Geographic Atrophy is a chronic and progressive eye condition that eventually culminates in blindness. Currently there is no available treatment.

The company is a spinout from The University of Manchester. It was founded by Professor Paul Bishop, Professor Simon J. Clark and Dr Richard Unwin, who have international reputations and world-leading Complement System expertise.

HTP were briefed by the founders to develop a website that would help attract funding to pursue further research and at the same time educate and inform visitors about Complement System diseases – especially Geographic Atrophy – and the potential of the company’s work to benefit the lives of millions.

In 2022 Complement Therapeutics was awarded seed finance of 5 million euros to fund further pre-clinical and early clinical development. The company continues to pursue its ground-breaking work, now through a considerably expanded team.

In 2022 Complement Therapeutics was awarded seed finance of 5 million euros to fund further pre-clinical and early clinical development. The company continues to pursue its ground-breaking work, now through a considerably expanded team.

Colony
5 Piccadilly Place
Manchester M1 3BR
HTP Digital science and technology marketing specialists
CONTACT